Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

376
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
376
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

12.9K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12.9K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

8.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
8.0K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

8.5K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.7K
Pharmacovigilance01:19

Pharmacovigilance

2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-scale data improves performance of machine learning model for long COVID identification.

Communications medicine·2026
Same author

Governing real-world health data as a public utility.

Science (New York, N.Y.)·2026
Same author

LPGGNet: Learning from Local-Partition-Global Graph Representations for Motor Imagery EEG Recognition.

Brain sciences·2025
Same author

LinkML: an open data modeling framework.

GigaScience·2025
Same author

Development of a robust corpus for automated evaluation of online health information in Chinese using the DISCERN scale.

Journal of the American Medical Informatics Association : JAMIA·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025

Related Experiment Video

Updated: Apr 15, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Mining severe drug-drug interaction adverse events using Semantic Web technologies: a case study.

Guoqian Jiang1, Hongfang Liu1, Harold R Solbrig1

  • 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA.

Biodata Mining
|April 2, 2015
PubMed
Summary

This study developed a Semantic Web approach to identify severe drug-drug interaction-induced adverse drug events (DDIs-ADEs), crucial for prioritizing medical needs and enhancing pharmacovigilance.

Keywords:
Adverse drug eventData miningDrug-drug InteractionElectronic medical recordsSemantic web technology

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

2.3K

Related Experiment Videos

Last Updated: Apr 15, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

2.3K

Area of Science:

  • Pharmacovigilance
  • Drug Safety
  • Semantic Web Technologies

Background:

  • Drug-drug interactions (DDIs) are a significant cause of adverse drug events (ADEs).
  • Existing knowledge resources often lack severity information for ADEs, hindering medical need prioritization.
  • There is a critical need for methods to identify and classify severe DDI-induced ADEs.

Purpose of the Study:

  • To develop and evaluate a Semantic Web-based approach for mining severe DDI-induced ADEs.
  • To classify the severity of DDI-induced ADEs using a standardized grading system.
  • To support translational and pharmacovigilance studies of severe ADEs.

Main Methods:

  • Utilized a normalized FDA Adverse Event Report System (AERS) dataset.
  • Extracted DDI-ADE pairs and outcome codes for cardiovascular drugs (Warfarin, Clopidogrel, Simvastatin).
  • Filtered associations using SIDER and PharmGKB ADE datasets, performed signal enrichment with EMR data, and classified ADEs using CTCAE in OWL.

Main Results:

  • Identified 601 DDI-ADE pairs for the three drugs.
  • Classified 61 pairs as Grade 5, 56 as Grade 4, and 484 as Grade 3 severity.
  • Detected signals for 59 DDI-ADE pairs using EMR data.

Conclusions:

  • The developed Semantic Web approach effectively identifies severe DDI-induced ADEs.
  • This method can be generalized to other drug domains for pharmacovigilance.
  • The approach aids in prioritizing medical needs and advancing drug safety research.